+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pilot trials of ZD1839 , an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with mitoxantrone/prednisone or docetaxel/estramustine in patients with hormone-refractory prostate cancer



Pilot trials of ZD1839 , an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with mitoxantrone/prednisone or docetaxel/estramustine in patients with hormone-refractory prostate cancer



Journal of Urology 169(4 Suppl.): 244




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035504441

Download citation: RISBibTeXText


Related references

ZD1839 , an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor , is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours Preliminary tolerability, efficacy and pharmacokinetic results. European Journal of Cancer 37(Suppl. 6): S30-S31, 2001

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorganic and Medicinal Chemistry Letters 11(14): 1911-1914, 2001

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clinical Pharmacokinetics 40(4): 297-306, 2001

Phase II randomised trial of docetaxel , estramustine and prednisone Two schedules - versus mitoxantrone and prednisone in patients with hormone refractory prostate cancer. European Urology Suppl.s 2(1): 189, 2003

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology 23(15): 3343-3351, 2005

Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. Annals of Oncology 16(3): 419-424, 2005

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Seminars in Oncology 29(1 Suppl 4): 37-46, 2002

Prostate cancer cell proliferation is strongly reduced by combination treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and the anti-androgen bicalutamide. EJC Suppl.s 1(5): S265, 2003

Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clinical Cancer Research 9(4): 1566-1572, 2003

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. Journal of Clinical Oncology 20(9): 2240-2250, 2002

Epidermal growth factor receptor tyrosine kinase inhibitor , ZD1839 , in combination with 5-fluorouracil and leucovorin , in advanced colorectal cancer. European Journal of Cancer 37(Suppl. 6): S18-S19, 2001

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clinical Cancer Research 9(6): 2040-2048, 2003

Second-line combination chemotherapy: A phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC) refractory to docetaxel-based therapy. Journal of Clinical Oncology 26(15_Suppl): 5151-5151, 2016

The selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 blocks estrogen receptor/growth factor cross-talk implicated in tamoxifen resistance in breast cancer. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1001, 2002